Arsène‐Bienvenu Loembé

541 total citations
15 papers, 377 citations indexed

About

Arsène‐Bienvenu Loembé is a scholar working on Hepatology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Arsène‐Bienvenu Loembé has authored 15 papers receiving a total of 377 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hepatology, 7 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Arsène‐Bienvenu Loembé's work include Hepatocellular Carcinoma Treatment and Prognosis (8 papers), Liver physiology and pathology (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). Arsène‐Bienvenu Loembé is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (8 papers), Liver physiology and pathology (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). Arsène‐Bienvenu Loembé collaborates with scholars based in United Kingdom, Germany and South Korea. Arsène‐Bienvenu Loembé's co-authors include Emma Dean, Simon A. Smith, Peter G. Mortimer, Minsuk Kwon, Ann‐Lii Cheng, Tim Meyer, Daniel H. Palmer, Chia‐Jui Yen, Jeeyun Lee and Jung Yong Hong and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Arsène‐Bienvenu Loembé

15 papers receiving 372 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arsène‐Bienvenu Loembé United Kingdom 9 196 168 100 88 42 15 377
Hajrah Khawaja United Kingdom 7 115 0.6× 147 0.9× 57 0.6× 73 0.8× 41 1.0× 8 272
Wen-Son Hsieh United States 6 177 0.9× 135 0.8× 138 1.4× 56 0.6× 75 1.8× 9 329
Karin Berghoff Germany 8 134 0.7× 120 0.7× 123 1.2× 69 0.8× 43 1.0× 28 277
Soheil Yala United States 4 119 0.6× 171 1.0× 103 1.0× 98 1.1× 34 0.8× 6 288
Antonio Gnoni Italy 7 162 0.8× 124 0.7× 76 0.8× 99 1.1× 58 1.4× 9 372
Tongguo Si China 13 153 0.8× 75 0.4× 146 1.5× 126 1.4× 50 1.2× 29 405
Stephen Eppler United States 8 143 0.7× 188 1.1× 44 0.4× 45 0.5× 23 0.5× 9 404
Carina Hage Switzerland 6 135 0.7× 171 1.0× 71 0.7× 51 0.6× 23 0.5× 7 342
Davide Bosso Italy 12 132 0.7× 133 0.8× 167 1.7× 29 0.3× 21 0.5× 18 366
Sabina Delcuratolo Italy 9 153 0.8× 127 0.8× 69 0.7× 72 0.8× 38 0.9× 14 333

Countries citing papers authored by Arsène‐Bienvenu Loembé

Since Specialization
Citations

This map shows the geographic impact of Arsène‐Bienvenu Loembé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arsène‐Bienvenu Loembé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arsène‐Bienvenu Loembé more than expected).

Fields of papers citing papers by Arsène‐Bienvenu Loembé

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arsène‐Bienvenu Loembé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arsène‐Bienvenu Loembé. The network helps show where Arsène‐Bienvenu Loembé may publish in the future.

Co-authorship network of co-authors of Arsène‐Bienvenu Loembé

This figure shows the co-authorship network connecting the top 25 collaborators of Arsène‐Bienvenu Loembé. A scholar is included among the top collaborators of Arsène‐Bienvenu Loembé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arsène‐Bienvenu Loembé. Arsène‐Bienvenu Loembé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Kwon, Minsuk, Ryul Kim, Kyu‐Tae Kim, et al.. (2022). Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. Journal for ImmunoTherapy of Cancer. 10(7). e005041–e005041. 59 indexed citations
2.
Kim, Seung Tae, Simon A. Smith, Peter G. Mortimer, et al.. (2021). Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. Clinical Cancer Research. 27(17). 4700–4709. 61 indexed citations
3.
Kwon, Minsuk, Minae An, S.T. Kim, et al.. (2021). Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy. Annals of Oncology. 33(2). 193–203. 81 indexed citations
4.
5.
Förster, Martin, Allan Hackshaw, Tommaso De Pas, et al.. (2018). A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3). Lung Cancer. 120. 27–33. 22 indexed citations
6.
7.
8.
9.
Okusaka, Takuji, Taiga Otsuka, Hideki Ueno, et al.. (2016). Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. Cancer Science. 107(12). 1791–1799. 6 indexed citations
10.
11.
Palmer, Daniel H., Yuk Ting, Markus Peck‐Radosavljevic, et al.. (2015). Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 33(3_suppl). 238–238. 13 indexed citations
12.
Cheng, Ann‐Lii, Chia‐Jui Yen, Tae‐You Kim, et al.. (2015). Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.. Journal of Clinical Oncology. 33(3_suppl). 339–339. 13 indexed citations
13.
Scagliotti, Giorgio V., Natasha B. Leighl, Anna K. Nowak, et al.. (2014). Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study.. Journal of Clinical Oncology. 32(15_suppl). TPS7612–TPS7612. 2 indexed citations
14.
Eisen, Tim, Yaroslav Shparyk, Nicholas MacLeod, et al.. (2013). Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Investigational New Drugs. 31(5). 1283–1293. 48 indexed citations
15.
Palmer, Daniel H., et al.. (2012). Phase I Study of Nintedanib (BIBF 1120) in European Patients with advanced Hepatocellular Carcinoma. Annals of Oncology. 23. ix245–ix245. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hajrah Khawaja Breakdown of academic impact, for papers by Wen-Son Hsieh Breakdown of academic impact, for papers by Karin Berghoff Breakdown of academic impact, for papers by Soheil Yala Breakdown of academic impact, for papers by Antonio Gnoni Breakdown of academic impact, for papers by Tongguo Si Breakdown of academic impact, for papers by Stephen Eppler Breakdown of academic impact, for papers by Carina Hage Breakdown of academic impact, for papers by Davide Bosso Breakdown of academic impact, for papers by Sabina Delcuratolo
Rankless by CCL
2026